Piper Sandler raised the firm’s price target on PacBio (PACB) to $2 from $1.50 and keeps a Neutral rating on the shares. The firm cites the company’s quarterly results for the price target change.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio price target raised to $2 from $1.80 at Stephens
- Pacific Biosciences’ Earnings Call: Mixed Results and Strategic Outlook
- Pacific Biosciences: Overcoming Short-Term Challenges with Strategic Innovations and Long-Term Growth Prospects
- Pacific Biosciences: Strong Consumable Growth and New Product Launches Drive Buy Rating
- Pacific Biosciences Reports Q3 2025 Financial Results